HSR25-156: Myelosuppression and Healthcare Resource Utilization in Community Oncology Patients With Limited-Stage Small Cell Lung Cancer (LS-SCLC) Receiving First-Line Therapy With or Without Trilaciclib
"HSR25-156: Myelosuppression and Healthcare Resource Utilization in Community Oncology Patients With Limited-Stage Small Cell Lung Cancer (LS-SCLC) Receiving First-Line Therapy With or Without Trilaciclib" published on 28 Mar 2025 by National Comprehensive Cancer Network.
Authors
- Susan O’Brien (ORCID: https://orcid.org/0000-0002-2481-7504)
- Ajeet Gajra (ORCID: https://orcid.org/0000-0002-5929-0466)
- Huan Huang (ORCID: https://orcid.org/0000-0002-5249-3156)
- Anna Carey (ORCID: https://orcid.org/0000-0001-6735-6077)
- Michelle Moore (ORCID: https://orcid.org/0009-0008-6431-6270)
- Peter R. Reeves (ORCID: https://orcid.org/0000-0003-4479-7974)
Institutions
- Triangle (US)
- Hematology Oncology Associates of Central New York (US)
- CancerCare (US)
- G1 Therapeutics (United States) (US)
- Digital Research Alliance of Canada
Publication Details
- Journal
- Journal of the National Comprehensive Cancer Network
- Published
- 2025-03-28
- DOI
- https://doi.org/10.6004/jnccn.2024.7175
- Primary Topic
- Cancer Treatment and Pharmacology
- Type
- article
- Field-Weighted Citation Impact
- 0.00